ⅢA-N2期肺癌新辅助化疗前后Ki-67表达水平与预后关系  

Relationship between the expression of Ki-67 and the effect before and after neoadjuvant chemotherapy on IIIA-N2 non-small cell lung cancer

作　　者：魏玉磊[1] 刘腾飞 韩媛媛[1] 袁伟[1] 王宇琛[1] 郑茂东[3] 董跃华[1] 张振明[1] WEI Yu-lei;LIU Teng-fei;HAN Yuan-yuan;YUAN Wei;WANG Yu-chen;ZHENG Mao-dong;DONG Yue-hua;ZHANG Zhen-ming(Department of Cardiothoracic Surgery,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China;Department of Emergency,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China;Department of Pharmacy,the First Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075000,China)

机构地区：[1]河北北方学院附属第一医院胸心外科,河北张家口075000 [2]河北北方学院附属第一医院急诊科,河北张家口075000 [3]河北北方学院附属第一医院药剂科,河北张家口075000

出　　处：《临床肺科杂志》2021年第1期109-113,共5页Journal of Clinical Pulmonary Medicine

基　　金：2019年度张家口市科技局项目(No.1921056D)。

摘　　要：目的探讨ⅢA-N2期非小细胞肺癌(NSCLC)新辅助化疗(NCT)前后Ki-67表达水平与预后的关系。方法收集60例ⅢA-N2期NSCLC患者,首先进行新辅助化疗(NCT),再行手术。观察NCT疗效,比较Ki-67表达与临床疗效和预后的关系。结果NCT客观缓解率(ORR)是53.3%。NCT前后癌组织中Ki-67表达阳性率分别为63.2%和43.9%(P<0.05)。临床疗效显著组与疗效不显效组比较,Ki-67表达阳性率较低(31.3%vs 60.0%)(P<0.05)。生存分析显示:Ki-67表达阴性者具有更好的OS和PFS(P<0.01)。单因素分析示:Ki-67表达阴性者有更高的2年PFS和OS。多因素分析示:Ki-67阴性表达是预后的独立危险因素。结论Ki-67表达水平影响临床疗效和预后,Ki-67可作为NSCLC新辅助化疗疗效预测指标。Objective To investigate the relationship between the expression of Ki-67 and clinical effect and prognosis before and after neoadjuvant chemotherapy at stage IIIA-N2 non-small cell lung cancer.Methods A total of 60 patients with stage IIIA-N2 non-small cell lung cancer were collected.Patients were treated with neoadjuvant chemotherapy and surgical treatment.NCT efficacy was observed,and the relationship between Ki-67 expression and clinical efficacy and prognosis was compared.Results The effective rate of neoadjuvant chemotherapy(CR+PR)was 53.3%.The positive rate of Ki-67 expression in cancer tissues before and after neoadjuvant chemotherapy was 63.2%and 43.9%(P<0.05).Compared with the group with significant clinical effect and the group with non-therapeutic,the positive rate of Ki-67 expression was lower(31.3%vs 60.0%).According to Ki-67 expression grouping,survival analysis showed that patients with Ki-67 negative expression had higher OS and PFS(P<0.01).Univariate analysis showed that the negative expression of Ki-67 had a higher PFS and OS with 2 years.Multivariate analysis showed that negative expression of Ki-67 was an independent risk factor for prognosis(P<0.01).Conclusion The expression of Ki-67 affects clinical efficacy and prognosis and can be used as a prognostic marker for neoadjuvant chemotherapy in lung cancer.

关 键 词：KI-67 新辅助化疗 ⅢA-N2 非小细胞肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]